In the News

1855 News Items found
Dr. Alexander Drilon
The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.
Sammy gets ready to swing a bat
Thanks to MSK’s expertise in treating young people with cancer, 16-year-old high school athlete Sammy is back to doing what he loves.
A masked nurse holds a card that says “thanks” in bright colors
2023 MSK Giving
In 2023, the MSK Giving community raised a record-breaking $1 billion — 100% of which will support our mission of ending cancer for life.
Seen are Scott Stuart, MSK Chair, Board of Trustees, and Selwyn M. Vickers, MD, FACS, President and CEO of MSK
The President and CEO and Chair of the Board at Memorial Sloan Kettering Cancer Center introduce the year's highlights in their introductory letter to the 2023 Annual Report.
MSK biochemist and imaging specialist Kayvan Keshari and biomedical engineer Daniel Heller.
Education
A New Breed of Cancer Fighters
Read about a first-of-its kind PhD program that enables aspiring scientists to tackle tough cancer problems.
MSK patient Marc Scarduffa seen holding his dog at the beach.
Learn how MSK is Improving patients’ quality of life with less toxic treatments.
Male AML patient kneeling next to dog outside.
In the Clinic
Controlling a Relentless Leukemia
Read about new targets and tactics for treating acute myeloid leukemia.
Jakki Stout stands in her white coat and holds a sign for the nurses’ suite that was named after her.
Learn about Jakki Stout’s journey from MSK nurse practitioner to breast cancer patient and back to being an even more helpful and inspiring nurse at MSK.
Dr. Sohrab Shah and trainees
Learn how computational biology and advances in artificial intelligence at MSK are improving cancer care from immunotherapy and radiation treatments to diagnostic scans and tests.
Pedro Lara with his arms in the air
Learn how MSK is improving the success of stem cell transplants from partially matched donors. This is especially important for diverse populations that can’t find full matches.